REGKIRONA

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Romania.

Active ingredients

The drug REGKIRONA contains one active pharmaceutical ingredient (API):

1	Regdanvimab UNII I0BGE6P6I6 - REGDANVIMAB
	Regdanvimab is a recombinant human IgG1 monoclonal antibody that binds to the receptor binding domain (RBD) of the spike(s) protein of SARS-CoV-2 consequently blocking cellular entry and SARS-CoV-2 infection.
	Read more about Regdanvimab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
REGKIRONA Concentrate for solution for infusion	MPI, EU: SmPC
REGKIRONA Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J06BD06		J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BD Antiviral monoclonal antibodies
Discover more medicines within J06BD06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1865011
FR	Base de données publique des médicaments	64499822
IT	Agenzia del Farmaco	049765011
LT	Valstybinė vaistų kontrolės tarnyba	1093628
PL	Rejestru Produktów Leczniczych	100459976
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68266001